Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 06-Mar-13 2:50 PM View:  | Novo A/s 10% Owner | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 4,720,060 | -- | -- | (100%) 4.72M to 0 | |
| 05-Mar-13 7:46 PM View: | Pagano Russell P. VP, Reg. & Clinical Affairs | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Option Exercise | 70,000 | $2.08 | $145,600.00 | 1042% 6.72K to 76.72K | |
| 05-Mar-13 7:34 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 1,392,920 | -- | -- | (94%) 1.48M to 83.17K | |
| 05-Mar-13 7:49 PM View: | Friedlaender Gary E Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Payment of Exercise | 17,774 | $9.07 | $161,210.00 | (100%) 17.77K to 0 | (5%) |
| 05-Mar-13 7:48 PM View: | Federico Charles Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Option Exercise | 38,736 | $4.16 | $161,269.00 | 3603% 1.07K to 39.81K | |
| 05-Mar-13 7:43 PM View: | Murphy James G Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 56,964 | -- | -- | (100%) 56.96K to 0 | |
| 05-Mar-13 7:36 PM View: | Bullock Lawrence E Chief Financial Officer | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 21,000 | -- | -- | (100%) 21.0K to 0 | |
| 05-Mar-13 7:46 PM View: | Pagano Russell P. VP, Reg. & Clinical Affairs | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 44,411 | -- | -- | (58%) 76.72K to 32.3K | |
| 05-Mar-13 7:49 PM View: | Friedlaender Gary E Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 64,957 | -- | -- | (54%) 121.28K to 56.32K | |
| 05-Mar-13 7:34 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 5,550 | -- | -- | (7%) 83.17K to 77.62K | |
| 05-Mar-13 7:48 PM View: | Federico Charles Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 27,834 | -- | -- | (70%) 39.81K to 11.98K | |
| 05-Mar-13 7:40 PM View: | Papasan Larry W Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Option Exercise | 38,736 | $4.16 | $161,269.00 | 126% 30.78K to 69.52K | |
| 05-Mar-13 7:42 PM View: | Watson Douglas G Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 96,021 | -- | -- | (100%) 96.02K to 0 | |
| 05-Mar-13 7:42 PM View: | Watson Douglas G Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Option Exercise | 38,736 | $4.16 | $161,269.00 | 68% 57.28K to 96.02K | |
| 05-Mar-13 7:49 PM View: | Friedlaender Gary E Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Option Exercise | 38,736 | $4.16 | $161,269.00 | 47% 82.54K to 121.28K | |
| 05-Mar-13 6:38 PM View: | Ehrlich Christopher B Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 1,250 | -- | -- | (< 1%) 1.83M to 1.83M | |
| 05-Mar-13 7:34 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Option Exercise | 221,000 | $2.40 | $530,570.00 | 18% 1.26M to 1.48M | |
| 05-Mar-13 7:46 PM View: | Pagano Russell P. VP, Reg. & Clinical Affairs | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Payment of Exercise | 32,305 | $9.07 | $293,129.00 | (100%) 32.3K to 0 | (5%) |
| 05-Mar-13 7:49 PM View: | Friedlaender Gary E Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 38,549 | -- | -- | (68%) 56.32K to 17.77K | |
| 05-Mar-13 7:40 PM View: | Papasan Larry W Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 69,517 | -- | -- | (100%) 69.52K to 0 | |
| 05-Mar-13 7:34 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Payment of Exercise | 77,623 | $9.07 | $704,336.00 | (100%) 77.62K to 0 | (5%) |
| 05-Mar-13 7:48 PM View: | Federico Charles Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Payment of Exercise | 11,977 | $9.07 | $108,677.00 | (100%) 11.98K to 0 | (5%) |
| 06-Mar-13 2:47 PM View: | Christensen Thorkil K. Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 2,507 | -- | -- | (100%) 2.51K to 0 | |
| 05-Mar-13 7:43 PM View: | Murphy James G Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Option Exercise | 38,736 | $4.16 | $161,269.00 | 213% 18.23K to 56.96K | |
| 05-Mar-13 7:36 PM View: | Bullock Lawrence E Chief Financial Officer | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 89,151 | -- | -- | (81%) 110.15K to 21.0K | |
| 05-Mar-13 6:38 PM View: | Ehrlich Christopher B Director | BioMimetic Therapeutics Inc. (BMTI) | 01-Mar-13 | Disposition | 1,830,250 | -- | -- | (100%) 1.83M to 0 | |
| 24-Jan-13 3:50 PM View: | Pagano Russell P. VP, Reg. & Clinical Affairs | BioMimetic Therapeutics Inc. (BMTI) | 22-Jan-13 | Market Sale (Planned) | 1,381 | $8.10 | $11,187.50 | (17%) 8.1K to 6.72K | 1% |
| 04-Apr-12 9:44 AM View: | Friedlaender Gary E Director | BioMimetic Therapeutics Inc. (BMTI) | 02-Apr-12 | Market Purchase | 10,000 | $2.79 | $27,923.00 | 14% 69.17K to 79.17K | 157% |
| 30-Mar-12 5:44 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 30-Mar-12 | Market Purchase | 39,362 | $2.43 | $95,632.50 | 3% 1.21M to 1.24M | 195% |
| 30-Mar-12 5:44 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 29-Mar-12 | Market Purchase | 30,638 | $2.38 | $72,890.90 | 3% 1.17M to 1.21M | 202% |
| 16-Apr-12 4:38 PM View: | Pagano Russell P. VP, Reg. & Clinical Affairs | BioMimetic Therapeutics Inc. (BMTI) | 29-Mar-12 | Market Sale (Planned) | 3,438 | $2.36 | $8,128.46 | (36%) 9.43K to 6.0K | (204%) |
| 28-Mar-12 5:55 PM View: | Douglas Earl Martin General Counsel | BioMimetic Therapeutics Inc. (BMTI) | 28-Mar-12 | Market Sale | 47,461 | $2.36 | $111,772.00 | (81%) 58.52K to 11.06K | (205%) |
| 29-Mar-12 5:47 PM View: | Papasan Larry W Director | BioMimetic Therapeutics Inc. (BMTI) | 27-Mar-12 | Market Purchase | 10,400 | $2.32 | $24,147.40 | 51% 20.38K to 30.78K | 209% |
| 28-Mar-12 5:55 PM View: | Douglas Earl Martin General Counsel | BioMimetic Therapeutics Inc. (BMTI) | 27-Mar-12 | Market Sale | 5,000 | $2.34 | $11,700.00 | (8%) 63.52K to 58.52K | (207%) |
| 28-Mar-12 5:55 PM View: | Douglas Earl Martin General Counsel | BioMimetic Therapeutics Inc. (BMTI) | 26-Mar-12 | Market Sale | 1,100 | $2.35 | $2,585.00 | (2%) 64.62K to 63.52K | (205%) |
| 28-Mar-12 5:56 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 23-Mar-12 | Market Purchase | 12,700 | $2.35 | $29,845.00 | 1% 1.16M to 1.17M | 205% |
| 28-Mar-12 5:56 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 23-Mar-12 | Market Purchase | 450 | $2.35 | $1,057.50 | < 1% 1.17M to 1.17M | 205% |
| 21-Mar-12 1:46 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 20-Mar-12 | Acquisition (other) | 42,269 | -- | -- | 3% 1.3M to 1.35M | |
| 21-Mar-12 1:46 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 20-Mar-12 | Gift | 100,000 | -- | -- | 8% 1.2M to 1.3M | |
| 21-Mar-12 1:46 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 20-Mar-12 | Disposition (other) | 42,269 | -- | -- | (3%) 1.25M to 1.2M | |
| 21-Mar-12 1:48 PM View: | Bullock Lawrence E Chief Financial Officer | BioMimetic Therapeutics Inc. (BMTI) | 20-Mar-12 | Market Purchase | 17,670 | $2.20 | $38,874.00 | 20% 89.05K to 106.72K | 226% |
| 21-Mar-12 1:46 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 20-Mar-12 | Gift | 100,000 | -- | -- | (7%) 1.35M to 1.25M | |
| 21-Mar-12 1:47 PM View: | Friedlaender Gary E Director | BioMimetic Therapeutics Inc. (BMTI) | 19-Mar-12 | Market Purchase | 10,000 | $2.19 | $21,869.00 | 17% 59.17K to 69.17K | 228% |
| 21-Mar-12 1:48 PM View: | Bullock Lawrence E Chief Financial Officer | BioMimetic Therapeutics Inc. (BMTI) | 19-Mar-12 | Market Purchase | 2,330 | $2.20 | $5,126.00 | 3% 86.72K to 89.05K | 226% |
| 21-Mar-12 1:47 PM View: | Friedlaender Gary E Director | BioMimetic Therapeutics Inc. (BMTI) | 19-Mar-12 | Market Purchase | 5,000 | $2.20 | $10,983.50 | 9% 54.17K to 59.17K | 227% |
| 13-Feb-12 5:51 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 16-Nov-11 | Gift | 112,072 | -- | -- | (9%) 1.27M to 1.16M | |
| 13-Feb-12 5:51 PM View: | Lynch Samuel Eugene President and CEO Director | BioMimetic Therapeutics Inc. (BMTI) | 16-Nov-11 | Gift | 112,072 | -- | -- | 10% 1.16M to 1.27M | |
| 14-Oct-11 4:39 PM View: | Douglas Earl Martin General Counsel | BioMimetic Therapeutics Inc. (BMTI) | 14-Oct-11 | Market Sale (Planned) | 3,000 | $3.06 | $9,166.50 | (5%) 60.14K to 57.14K | (135%) |
| 14-Oct-11 4:39 PM View: | Douglas Earl Martin General Counsel | BioMimetic Therapeutics Inc. (BMTI) | 13-Oct-11 | Market Sale (Planned) | 3,000 | $2.98 | $8,941.50 | (5%) 63.14K to 60.14K | (141%) |
| 14-Oct-11 4:39 PM View: | Douglas Earl Martin General Counsel | BioMimetic Therapeutics Inc. (BMTI) | 12-Oct-11 | Market Sale (Planned) | 3,000 | $2.99 | $8,970.90 | (5%) 66.14K to 63.14K | (140%) |
